Zeitschrift für entzündliche Darmerkrankungen und -störungen

Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract with a multifactorial etiology. Emerging evidence suggests that gut microbiota plays a critical role in the pathogenesis and management of IBD. This review aims to provide a comprehensive overview of current research on the role of gut microbiota in IBD, focusing on its contributions to disease development, progression, and potential therapeutic interventions. Alterations in the gut microbiota composition, characterized by dysbiosis, have been implicated in the disruption of intestinal homeostasis and immune responses. Therapeutic strategies targeting gut microbiota, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, have shown promise in modulating disease activity and promoting remission. Understanding the complex interactions between gut microbiota and the host immune system may lead to novel therapeutic approaches for IBD.

Inflammatory Bowel Disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract influenced by a complex interplay of genetic and environmental factors. This review explores the current understanding of genetic susceptibility and environmental triggers in the development of IBD. Advances in genomic research have identified numerous susceptibility loci, highlighting the role of genes involved in immune regulation and epithelial barrier function. Concurrently, environmental factors such as diet, microbiota, smoking, and stress have been shown to significantly modulate disease onset and progression. Understanding the interplay between genetic and environmental factors is crucial for developing targeted prevention and treatment strategies for IBD.

Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), presents significant diagnostic and prognostic challenges due to its complex and heterogeneous nature. This comprehensive review aims to evaluate and synthesize recent advancements in the identification and application of emerging biomarkers for the diagnosis and prognosis of IBD. Through a systematic review of the literature, we identified a range of promising biomarkers, including genetic markers, serum proteins, fecal markers, and microbiota profiles. These biomarkers have demonstrated potential in distinguishing IBD from other gastrointestinal disorders, monitoring disease activity, and predicting patient outcomes. The integration of these novel biomarkers into clinical practice holds promise for enhancing the precision of IBD diagnosis and prognosis, ultimately leading to more personalized and effective patient care. Further research and validation studies are necessary to translate these findings into routine clinical application, ensuring standardized methods and reference ranges for reliable use.

Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition that significantly impacts patients' quality of life. Biologic therapies have revolutionized the management of IBD by targeting specific components of the immune system. This review provides an overview of the latest advances in biologic therapies for IBD, focusing on their efficacy and safety profiles. Recent biologics, including anti-TNF agents, integrin inhibitors and IL-12/23 inhibitors, have shown substantial efficacy in inducing and maintaining remission in IBD patients. However, their use is associated with potential risks, including infections and malignancies. Understanding the benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.